Haisco(SZ:002653) Ge Long Hui·2025-09-15 11:14Core Viewpoint - The company Haisco (002653.SZ) has received approval from the National Medical Products Administration for its innovative drug Anruikefen injection, which now includes a new indication for treating moderate to severe itching associated with chronic kidney disease in adult patients undergoing maintenance hemodialysis [1] Group 1 - The newly approved indication for Anruikefen injection will be included in the priority review and approval process starting from July 2024 [1] - Anruikefen injection was first approved in May 2025 for the indication of treating mild to moderate pain after abdominal surgery [1] - Phase III clinical trials for the indication of postoperative analgesia in orthopedic surgery are currently progressing smoothly [1]